戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ectious virus produced by RPE cells (10(6.5) TCID50/0.1 ml) significantly surpassed levels produced b
2 rpassed levels produced by HEL cells (10(5.5)TCID50/0.1 ml).
3 han when given at the regular dose, 10(7.26) TCID50 (40 participants); as a control, a placebo vaccin
4 ncentrations ranging from 10(1.4) to 10(4.4) TCID50/5 microliters were capable of inducing both infla
5  the highest concentration of virus (10(4.4) TCID50/5 microliters) in CD-1 mice resulted in only the
6 CTL response when given at a dose of 10(8.0) TCID50 (60 participants) than when given at the regular
7 from 0.01 50% tissue culture infective dose (TCID50) and were able to detect at least 1 TCID50 of ent
8 nts treated at high-dose levels (10(8)-10(9) TCID50), and their median overall survival of 26.5 month
9  determined by RT-qPCR and virion release by TCID50 assay.
10 8 (HHV-8) 50% tissue culture infective dose (TCID50) assay using the T1H6-DC-SIGN cell line.
11                                    HRV (1-10 TCID50/cell) significantly inhibited T cell proliferatio
12 to 10(9) 50% tissue culture infective doses (TCID50) consistently infected all the animals, and many
13 s, and many monkeys receiving 10(8) or 10(9) TCID50 developed paralysis.
14 ction of immature dendritic cells at various TCID50 doses.
15 immunodeficiency virus type 1 (HIV-1) and <1 TCID50 for simian immunodeficiency virus isolated from a
16 ml in the blood and between 10(6) and 10(10) TCID50/g tissue in the intestines, kidney, lungs, brain,
17 .5 log10 50% tissue culture infectious dose [TCID50]) in nasal wash viral titers and inflammation res
18   Viral antigen-specific ELISAs, qRT-PCR and TCID50 infectious assays were utilized to determine anti
19 166) were inoculated intranasally with 10(5) TCID50 influenza A/Texas/91 (H1N1) virus.
20 a-galactosidase, which was used to determine TCID50 levels.
21 ingle high doses ranging from 10(7) to 10(9) TCID50 Mahoney type 1 virus were infected, and many of t
22 urine blood (EBOV concentration of 1 x 10(7) TCID50 . ml(-1)) at 4:1 vol/vol buffer/sample ratios.
23 issue culture infective dose per milliliter [TCID50 . ml(-1)]) and murine blood (EBOV concentration o
24 x 10(-3) 50% tissue culture infective doses (TCID50)/ml of cultured MERS-CoV per reaction.
25 4 x 10(2) 50% tissue culture infective dose (TCID50)/ml, as well as the no-virus negative-control sam
26  x 10(5) 50% tissue culture infective doses (TCID50)/ml.
27                   Virus titers reached 10(8) TCID50/ml in the blood and between 10(6) and 10(10) TCID
28 50/mL, for a saturation value of ~4.801x10(3)TCID50/mL, with good repeatability and excellent specifi
29 tive results, was determined to be 4 x 10(2) TCID50/ml.
30                         Three doses of 106.5 TCID50 of ALVAC-CMV(gB) induced very low neutralizing or
31 gative adults randomly received either 106.8 TCID50 of ALVAC-CMV(gB) or 106.8 TCID50 of ALVAC-RG, exp
32 ) vector expressing HIV-1MN gp160 or 10(5.5) TCID50 of ALVAC-rabies virus glycoprotein control at 0 a
33 ither 106.8 TCID50 of ALVAC-CMV(gB) or 106.8 TCID50 of ALVAC-RG, expressing the rabies glycoprotein,
34 tion against experimental challenge with 107 TCID50 of attenuated H1N1 (vaccine strain) by intranasal
35                           Two doses of 10(7) TCID50 of ca influenza virus infected all infants, indic
36 ho were randomized to receive 10(6) or 10(7) TCID50 of canarypox (ALVAC) vector expressing HIV-1MN gp
37  (TCID50) and were able to detect at least 1 TCID50 of enterovirus in cerebrospinal fluid, stool, or
38 nuclear cells (PBMC) were challenged with 10 TCID50 of HIV-1MN or HIV-1BaL, titered in PBMC from norm
39 ety and immunogenicity of two doses of 10(7) TCID50 of live, attenuated cold-adapted (ca) influenza A
40 D50) of virus were estimated to be <1 and 10 TCID50 of MERS-CoV, respectively.
41          These data support the use of 10(8) TCID50 of MVA-BN in this population.
42 0 subjects received vaccine containing 10(8) TCID50 of MVA-BN, and 4 subjects received placebo.
43 by intraperitoneal (i.p.) injection of 10(5) TCID50 of SHRV/ml.
44 s received a single intranasal dose (10(6.2) TCID50) of ca A/Kawasaki/9/86 (H1N1) or ca A/Los Angeles
45 10(7) median tissue culture infective doses (TCID50) of MVA-BN, 10 subjects received vaccine containi
46 in 10(6) 50% tissue culture infective doses (TCID50) of SHRV/ml, and adult zebrafish were susceptible
47 ID50) per 0.05 mL], medium dose [7.5 x 10(4) TCID50 per 0.25 mL], or high dose [3.0 x 10(5) TCID50 pe
48 ID50 per 0.25 mL], or high dose [3.0 x 10(5) TCID50 per 1.0 mL]), or the active comparator-Priorix.
49 10(4) median tissue culture infection doses (TCID50) per 0.05 mL], medium dose [7.5 x 10(4) TCID50 pe
50 hy and 11 atopic asthmatic adults with 2,000 TCID50 RV-16.
51 l dose (LD50) was determined to be 0.015 50% TCID50 (tissue culture infective dose) of MARV/Ang-MA in
52 ybrid microchips was determined to be ~10(4) TCID50 titer/mL and 10(3)-10(4) EID50 titer/mL.
53                                Validation of TCID50 values was performed by immunofluorescence assay
54 x 10(-2) 50% tissue culture infective doses (TCID50), was developed.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。